Delivery Order SPE2DB20D3111-SPE2DB25FA8XN
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a contract value of $4,557.98. This firm fixed-price delivery order, with an ultimate completion date of July 30, 2025, represents a non-set-aside, competitively awarded procurement supporting federal medical supply needs. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) at a ceiling value of $1,846.22. This firm fixed-price delivery order, which is not set-aside, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be fulfilled from the...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Xifaxan 550 mg tablets (60-count) under a firm fixed price contract valued at $3,513.96, with an ultimate completion date of August 11, 2025. This non-set-aside award represents a routine pharmaceutical procurement supporting federal medical supply needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Xifaxan 550 mg tablets in unit dose packaging (60 count) with a ceiling value of $1,625.31. This competitively awarded, firm fixed price delivery order is scheduled for completion by July 24, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Xifaxan 550 mg tablets (60-count packages) under a firm fixed price contract valued at $4,888.67. This competitively awarded delivery order, with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count) under a firm fixed-price contract valued at $8,401.76, with an ultimate completion date of August 20, 2025. This non-set-aside competitive award was issued on August 19, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Xifaxan 550 mg tablets (60-count) under a firm fixed price contract with a ceiling value of $24,364.10 and an ultimate completion date of July 22, 2025. This is a non-set-aside competitive award, with performance to be executed at the vendor's Conshohocken, Pennsylvania location. The delivery order is issued as a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Xifaxan 550 mg tablets (60-count) with a ceiling value of $3,532.41. This competitive award, utilizing firm fixed-price terms, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 billion through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count) with a ceiling value of $1,954.87. The award was issued on July 21, 2025, with an ultimate completion date of July 22, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is to be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,438.43 on August 8, 2025, for the supply of Xifaxan 550 mg tablets (60-count packages). This is a firm fixed-price, competitive award with no set-aside designation and an ultimate completion date of August 11, 2025. The place of performance is the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract executed under AmerisourceBergen Drug Corp's...
- SPE2DB20D3111Indefinite Delivery Contract
- SPE2DB20D3111-SPE2DB25FA8XNDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a ceiling value of $20,573.32. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is categorized as a child contract under AmerisourceBergen's broader federal contract portfolio. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of August 15, 2025. This delivery order falls under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal medical supplier, AmerisourceBergen routinely fulfills military healthcare needs through this comprehensive global pharmaceutical support vehicle. The contract vehicle enables the company to supply a broad range of pharmaceutical products, including specialty medications and generic drugs, to support Defense Health Agency operations and other government healthcare systems. Xifaxan is a non-absorbed antibiotic used in treating traveler's diarrhea and hepatic encephalopathy, representing a standard pharmaceutical commodity within the company's extensive delivery order portfolio under this prime IDC.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $20.6k | 8/14/25 |